Skip to main content

Icosavax, Inc. (ICVX)

NASDAQ: ICVX · IEX Real-Time Price · USD
26.58 -1.13 (-4.08%)
Sep 22, 2021 2:05 PM EDT - Market open
Market Cap997.01M
Revenue (ttm)3.62M
Net Income (ttm)-21.23M
Shares Out37.51M
EPS (ttm)-0.57
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume84,998
Open27.70
Previous Close27.71
Day's Range25.06 - 28.00
52-Week Range21.70 - 49.99
Betan/a
Analystsn/a
Price Target50.00 (+88.1%)
Est. Earnings DateNov 15, 2021

About ICVX

Icosavax is a biopharmaceutical company leveraging our innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Our pipeline includes vaccine candidates targeting some of the most prevalent viral causes of pneumonia. We are developing these candidates for older adults, a patient population with high unmet need. Our vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of two different VLP candidates, designed to target resp...

IndustryBiotechnology
IPO DateJul 29, 2021
CEOAdam Simpson
Employees22
Stock ExchangeNASDAQ
Ticker SymbolICVX
Full Company Profile

Financial Performance

Financial Statements

News

Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain -

1 week ago - GlobeNewsWire

Icosavax Appoints Elizabeth Bekiroğlu to General Counsel

SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against...

1 week ago - GlobeNewsWire

Adams Street Partners Growth Equity Strategy Participates in Three High-Profile Public Offerings In Seven Days

MENLO PARK, Calif.--(BUSINESS WIRE)--Adams Street Partners, a private markets investment firm with $45 billion in assets under management, announced today that within a 7-day period last week three comp...

Other symbols:BASEHOOD
1 month ago - Business Wire

Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additiona...

SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against ...

1 month ago - GlobeNewsWire

Icosavax stock skyrockets 200% on first day of trading for newly public Seattle biotech company

Icosavax is having quite the debut as Washington state's newest public company.

1 month ago - GeekWire

Icosavax Announces Pricing of Upsized Initial Public Offering

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus ...

1 month ago - Business Wire

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

Seattle-based Icosavax has filed to go public by way of an IPO, simply 4 years after it launched out of the College of Washington.

2 months ago - ADMET

Icosavax IPO Registration Document (S-1)

Icosavax, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC